Combination of 2 Bioactive Compounds for Treatment of Breast Cancer: Triterpenoid Cucurbitacin I and Phenolic CAPE

Basit Öğe Kaydı
dc.authoridÜnüvar, Songül/0000-0001-8454-490X
dc.authoridKARAKUŞ, Fuat/0000-0002-5260-3650
dc.authorwosidÜnüvar, Songül/ABH-5516-2020
dc.authorwosidKARAKUŞ, Fuat/O-2627-2019
dc.contributor.authorKarakus, Fuat
dc.contributor.authorYilmaz, Kadir
dc.contributor.authorEyol, Ergul
dc.contributor.authorUnuvar, Songul
dc.date.accessioned2024-08-04T20:46:02Z
dc.date.available2024-08-04T20:46:02Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIt has been demonstrated that both cucurbitacin I (Cu I) and caffeic acid phenethyl ester (CAPE) have anticancer activities. The current study aimed to examine the proliferation, migration, and colony formation actions of Cu I and CAPE on MCF-7 and MDA-MB-231 human breast cancer cells. The antimigration, antiproliferative, and colony inhibition effects of different dosages of Cu I, CAPE, and Cu I + CAPE on cells were determined by the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) cell viability assay, wound healing, and colony formation assays, respectively. Compared with single treatment, combination of 2 bioactive compounds enhanced the anticancer activity. When Cu I and CAPE were combined, a strong inhibitor effect was shown on cell growth, colony formation, and cell migration compared with the compounds used singly. The concomitant treatment with Cu I and CAPE showed stronger antiproliferative activities on both MCF-7 and MDA-MB-231 cells compared with individual treatment with either Cu I or CAPE. Caffeic acid phenethyl ester is a specific inhibitor of Nuclear factor-kappa B (NF-kappa B). It shows anticancer activity depending on this inhibition. It is a bioactive phenolic compound that is derived from propolis. Cucurbitacin I is a selective Januskinase/signal transducer and a transcription-3 signal pathway inhibitor. Combination of these 2 natural anticancer compounds is beneficial in the treatment of cancer, as well as the side effects associated with classical chemotherapeutics not being observed with the use of these compounds.en_US
dc.identifier.doi10.1177/1934578X19857492
dc.identifier.issn1934-578X
dc.identifier.issn1555-9475
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85068609206en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1177/1934578X19857492
dc.identifier.urihttps://hdl.handle.net/11616/98861
dc.identifier.volume14en_US
dc.identifier.wosWOS:000475765700047en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofNatural Product Communicationsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcaffeic acid phenethyl esteren_US
dc.subjectbreast canceren_US
dc.subjectherbal medicineen_US
dc.subjectcombination therapyen_US
dc.subjectcucurbitacin-Ien_US
dc.titleCombination of 2 Bioactive Compounds for Treatment of Breast Cancer: Triterpenoid Cucurbitacin I and Phenolic CAPEen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu